Gene therapy developer Audentes Therapeutics (NASDAQ: [[ticker:BOLD]]) has promoted John Gray to senior vice president and chief scientific officer. Gray previously served as vice president of research and development for the San Francisco biotech. Before joining Audentes in 2014, Gray was assistant director of the Harvard Gene Therapy Initiative. Last year, Audentes raised $75 million in an initial public offering to fund clinical work on its gene therapies for rare diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
